Patents
US 12662464 B2: Degraders of cyclin-dependent kinase 12 (CDK12) and uses thereof
- Granted
- 2026-06-23
- Filed
- 2020-04-23 application 17604852
- Type
- Utility · 12 claims
- Elsewhere
- Google Patents ↗ · USPTO patent document ↗ · USPTO Patent Center record ↗
Abstract
Provided herein are bifunctional compounds with a moiety (e.g., lenalidomide, thalidomide) that is a binder of an E3 ubiquitin ligase (e.g., Cereblon) and another moiety that is a binder of a target protein (e.g., kinase (e.g., CDK (e.g., CDK9 and/or CDK12))) to induce degradation of the target protein CDK9 and/or CDK12. Also provided are pharmaceutical compositions comprising the bifunctional compounds, and methods of treating and/or preventing diseases (e.g., proliferative diseases, such as cancers (e.g., ovarian cancer, breast cancer, or prostate cancer))). Provided also are methods of inducing the degradation of the target protein (e.g., kinase (e.g., CDK (e.g., CDK9 and/or CDK12))), and methods of inducing apoptosis in a cell in a biological sample or subject by administering the bifunctional compound or composition described herein.
Source: PTBLXML, file of 2026-06-23 (ipgb20260623.xml).
Assignees
| Assignee | Type | Place | Also on furp.org | Source |
|---|---|---|---|---|
| DANA-FARBER CANCER INSTITUTE, INC. 892 patents | US company or organization | Boston, MA | DANA-FARBER CANCER INSTITUTE, INC. Federal lobbying client EXACT high confidence: identical full name and state DANA-FARBER CANCER INSTITUTE Nonprofit FUZZY medium confidence: same name (governing-board words and legal endings aside) and state | PTBLXML, file of 2026-06-23 |
Inventors
| Inventor | Place | Patents | Person page | Source |
|---|---|---|---|---|
| Jianwei Che | Sharon, MA | PTBLXML, file of 2026-06-23 | ||
| Nathanael S. Gray | Stanford, CA | 178 | PTBLXML, file of 2026-06-23 | |
| Tinghu Zhang | Brookline, MA | 62 | PTBLXML, file of 2026-06-23 | |
| Baishan Jiang | Brookline, MA | 7 | PTBLXML, file of 2026-06-23 | |
| Yang Gao | Boston, MA | PTBLXML, file of 2026-06-23 | ||
| Nicholas Paul Kwiatkowski | Brookline, MA | 28 | PTBLXML, file of 2026-06-23 |
CPC categories
| Subclass | Category | First group | Source |
|---|---|---|---|
| C07D | Heterocyclic compounds | C07D401/14 | PTBLXML, file of 2026-06-23 |
| A61K | Preparations for medical, dental or toiletry purposes | A61K45/06 | PTBLXML, file of 2026-06-23 |
Cooperative Patent Classification, as currently assigned (one row per subclass).
Assignments and security interests
| Recorded | What | From | To | Reel/frame | Source |
|---|---|---|---|---|---|
| 2022-09-28 | Assignment Assignment of assignor's interest | GRAY, NATHANAEL S. signed 2020-12-18 ZHANG, TINGHU signed 2020-08-13 JIANG, BAISHAN signed 2020-08-14 GAO, YANG signed 2020-08-14 KWIATKOWSKI, NICHOLAS PAUL signed 2020-09-25 CHE, JIANWEI signed 2020-08-13 | DANA-FARBER CANCER INSTITUTE, INC. BOSTON, MA | 61245/21 | PASDL, file of 2026-10-15 |
Documents recorded with the USPTO Assignment Recordation Branch that list this patent. A security interest is a lender’s claim on the patent as collateral; a release ends it.
USPTO bulk data: PatentsView granted patents, disambiguated (PVGPATDIS) for patents, assignees, inventors, places and CPC categories; the USPTO Patent Assignment Dataset (ECORSEXC) for assignments and security interests. Patents filed in the last 20 years. No claims or full text. Links to other records are by name (and state): EXACT means the identical full name and state; FUZZY means a looser name match, with the confidence shown.